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Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
CADASIL is caused by more than a hundred NOTCH3 mutations. Virtually all encoded mutant 
proteins contain an odd number of cysteines. As such, structural changes in NOTCH3 may be the 
primary molecular abnormality in CADASIL. Thus, we sought evidence for structurally altered 
NOTCH3 protein in CADASIL tissue. Four antibodies were raised in rabbits against two non-
overlapping N-terminal NOTCH3 sequences. These reagents were used in immunohistochemical 
experiments to detect epitopes in post-mortem CADASIL brains (n=8), control brains, and cells 
overexpressing NOTCH3. To determine the biochemical nature of NOTCH3 epitopes, we used 
these antibodies to probe pure NOTCH3-Fc fusion proteins treated with acid, urea, guanidinium, 
ionic detergents, acrylamide, and thiol- and phosphorus-based reductants. All antibodies avidly 
stained arteries in 8 of 8 CADASIL brain samples. The most prominent staining was in 
degenerating media of leptomeningeal arteries and sclerotic penetrating vessels. Normal appearing 
vessels from control brains were not reactive. Antibodies did not react with cultured cells 
overexpressing NOTCH3 or with purified NOTCH3-Fc protein. Furthermore, treatment of pure 
protein with acid, chaotropic denaturants, alkylators, and detergents failed to unmask N-terminal 
NOTCH3 epitopes. Antibodies, however, recognized novel N-terminal epitopes in purified 
NOTCH3-Fc protein treated with three different reductants (DTT, beta-mercaptoethanol, and 
*Corresponding author: Michael M. Wang, 7725 Med Sci II 5622, 1137 Catherine Street, Ann Arbor, MI 48109-5622 Phone: 
734-763-5453. Fax: 734-936-8813 micwang@umich.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Brain Res. Author manuscript; available in PMC 2015 October 02.
Published in final edited form as:
Brain Res. 2014 October 2; 1583: 230–236. doi:10.1016/j.brainres.2014.08.018.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
TCEP). We conclude that CADASIL arteries feature latent N-terminal NOTCH3 epitopes, 
suggesting the first evidence in vivo of NOTCH3 structural alterations.
1. Introduction
In 1996, Joutel and colleagues first described mutations in NOTCH3 in patients with 
CADASIL, an inherited disorder of smooth muscle cells that causes leukoencephalopathy 
and manifests as premature stroke and vascular dementia1. Since then, more than one 
hundred independent NOTCH3 mutations have been published 2, the overwhelming 
majority of which are missense mutations that change the number of cysteines in the 
predicted amino acid sequence3. This results in an uneven number of cysteine residues, 
which likely alters the tertiary structure of Notch3.
The primary sequence of NOTCH3 features a large extracellular domain which is the site of 
almost all mutations linked to CADASIL3. As in homologous related proteins (NOTCH1, 2, 
and 4), the NOTCH3 extracellular domain is composed of an array of more than thirty EGF-
like domains4. Each of these EGF-like domains contains six conserved cysteine residues. 
Notch EGF-like structures that have been elucidated at the atomic structural level feature six 
oxidized cysteine residues that form three pairs of disulfide bonds5, 6.
The conserved disulfide bonding of EGF-like repeats in other extracellular matrix 
proteins7, 8 suggests that disulfide pairing plays an important role in structural stability of 
NOTCH3. Introduction or elimination of a cysteine, which hallmarks most mutations seen in 
CADASIL, is predicted to impair normal disulfide pairing within the NOTCH3 ectodomain 
and, consequently, may seriously disrupt the structure of the protein. The ectodomain of 
NOTCH3, which harbors all known CADASIL mutations, accumulates in the blood vessels 
of patients 9. One potential mechanism of CADASIL pathogenesis, therefore, could be 
cysteine mutation-driven structural alterations of the protein that drives protein misfolding 
and accumulation. There is, however, no experimental evidence demonstrating structural 
alterations of NOTCH3 protein in human tissue.
We describe the discovery of novel N-terminal NOTCH3 epitopes in diseased arteries in 
human CADASIL brains. We show that these epitopes are undetectable in native NOTCH3 
protein, but can be unmasked specifically by disulfide bond disruption. Our studies suggest 
an important role of reduced cysteine in CADASIL pathogenesis.
2. Results
2.1 Identification of novel N-terminal NOTCH3 epitopes in CADASIL arteries
Two synthetic peptides were used to immunize rabbits (Figure 1A). Antisera 5209 and 5210 
were raised against the wild type C-terminal end of the first EGF-like domain. Antisera 2078 
and 2079 were raised against the N-terminal end of the second EGF-like domain that 
contained the canonical R90C CADASIL mutation. All four antisera reacted unequivocally 
at <1:2000 with 1 ug immobilized peptide immunogen.
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Antibodies were used for immunohistochemical analysis of CADASIL (n=8) and control 
brain samples (n=6). In CADASIL arteries, antisera reacted strongly with thickened white 
matter arteries (Figure 1B and 1C). The media of CADASIL leptomeningeal arteries also 
reacted strongly with NOTCH3 antibodies in vessel layers that contain degenerating smooth 
muscle (Figure 2A and 2C). Morphologically normal arteries of control brains did not react 
with antibodies (Figures 2B and 2D). Importantly, the 2078 and 2079 antisera, which were 
raised against a peptide containing the R90C mutation, reacted with the seven CADASIL 
brains which did not have the R90C mutation. Staining of a brain with the R90C mutations 
was not stronger than other samples, suggesting that the antibodies react with CADASIL 
arteries but are not specific for the R90C mutation.
Antibodies were also tested on cell lines overexpressing wild type or mutant NOTCH3 
(Figure 3) that were fixed and embedded in the same manner as brain tissues. 
Immunohistochemistry performed on these samples using all four antibodies to the N-
terminal sequences of NOTCH3 did not result in signal. This suggested that antibodies 
reacted with NOTCH3 epitopes generated by post-translational processes in vessels in 
CADASIL.
2.2 Unmasking of latent NOTCH3 N-terminal epitopes by protein reduction
We purified recombinant NOTCH3 ectodomain (EGF domains 1–27) fused to 
immunoglobulin Fc to apparent homogeneity using protein A chromatography. A wild type 
protein and the R90C point mutation-containing protein were analyzed after adsorbing 
proteins to nitrocellulose. None of the four antibodies recognized native or mutant NOTCH3 
ectodomain (UN in Figure 4).
We hypothesized that NOTCH3 could be modified from its native state to reveal latent 
epitopes in the N-terminus. To test this possibility, we chemically treated purified wildtype 
or R90C NOTCH3 fusions prior to probing with antibodies. Of the six biochemical 
treatments initially tested, only DTT converted wild type or mutant NOTCH3 to a form that 
was recognized by antibodies (Figure 4).
We then tested the effects of increasing concentrations of DTT, beta-mercaptoethanol (a 
thiol reductant) and TCEP (a phosphorus-based reductant) on NOTCH3 protein. All 
reductants efficiently converted both wildtype and R90C NOTCH3 to a form recognizable 
by all four antibodies (Figure 5).
Since antibodies only bound to reduced NOTCH3, it was possible that they interacted with 
thiol groups of NOTCH3. If this were the case, we would expect that reduction followed by 
alkylation of the protein would reduce antibody recognition. However, addition of alkylating 
agents acrylamide or iodoacetate after protein reduction did not affect antibody reactivity 
(Figure 6), suggesting that epitope recognition did not require protein thiols.
3. Discussion
CADASIL has been extensively studied because, in part, it is the most common small vessel 
disorder with an identified monogenic cause2. Stereotyped cysteine mutations in NOTCH3 
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and accumulation of NOTCH3 protein in vessels have suggested a proteinopathy involving 
NOTCH3, but changes in the protein structure of NOTCH3 have yet to be explored. Here, 
we present the first evidence of molecular changes in the NOTCH3 protein in CADASIL 
brain tissue.
Characteristics of NOTCH3 N-terminal epitopes
The molecular changes in NOTCH3 described herein were only found after protein 
reduction. Two classes of molecular changes could account for induction of latent epitopes 
by protein reduction: 1) an accessible (surface-exposed) region of the protein shifts 
conformation and 2) an inaccessible region of the protein moves to the surface of the protein 
and becomes accessible to antibodies. The antibodies we used were polyclonal and 
generated against peptides that likely adopt many conformations. It would be unlikely that 
all four polyclonal antibodies fail to bind accessible regions of the protein, particularly after 
exposure of the protein to multiple denaturing treatments (Figure 4). The absence of 
polyclonal antibody binding to native NOTCH3 is thus unlikely to result solely from a 
conformational change in an antibody-accessible N-terminal target region.
A more likely possibility is that epitopes are shielded in the native disulfide bonded protein 
and that reduction of disulfide bonds frees the molecule from structural constraints, allowing 
antibodies access to epitopes previously buried in the N-terminus. As cysteine alkylation 
failed to block antibody binding, the epitopes identified here do not interact with antibodies 
via reduced cysteines. Because the two peptides used to generate the antibodies are very 
close within the primary sequence, we further hypothesize that the end of the first EGF 
repeat and the beginning of the second EGF repeat are both sequestered, unavailable to 
antibodies, and may be in spatial proximity.
Potential mechanisms of N-terminal NOTCH3 epitope unmasking
The NOTCH3 N-terminal epitopes are abundant in CADASIL tissues but not normal-
appearing control vessels or cells overexpressing native NOTCH3. Moreover, antibodies 
raised against N-terminal sequences of NOTCH3 bind strongly to protein treated with 
reductants but not to native protein or denatured NOTCH3 that remains oxidized. Together, 
these findings suggest that vascular redox changes in NOTCH3 may be one of the potential 
mechanisms for N-terminal epitope unmasking in CADASIL. This possibility is further 
strengthened by the stereotyped molecular genetics of CADASIL, which support a critical 
role of NOTCH3 cysteine imbalance. If reducing conditions indeed regulate latency of 
NOTCH3 epitopes, two experimental findings need additional explanation.
First, why do both wildtype and mutant NOTCH3 require chemical reduction for recognition 
by antibodies? The most basic explanation is that a single cysteine mutation is insufficient to 
cause CADASIL N-terminal NOTCH3 epitope generation. Instead, multiple reduced 
cysteines (as in the case of chemically reduced proteins) must occur to generate CADASIL 
N-terminal NOTCH3 epitopes. In CADASIL, a single mutation may predispose the protein 
to further reduction which consequently results in unmasking of N-terminal NOTCH3 
epitopes.
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A second question raised by our results is: how does one explain the finding that the same 
N-terminal NOTCH3 epitopes are unmasked in CADASIL samples that include a wide 
range of cysteine mutations dispersed throughout NOTCH3? Any molecular mechanism 
must account for how multiple different NOTCH3 mutants each results in changes within 
this focal area of the protein which, in some cases, is far removed from the site of the 
mutation. In vessels, it is possible that disulfides throughout NOTCH3 may slowly 
isomerize by exchange of cysteine disulfide partners. Many secreted proteins (e.g. RNase, 
BPTI, TSP) are known to shuffle disulfide pairing. When mutant NOTCH3 containing an 
odd number of cysteines undergoes disulfide isomerization, reduced cysteines may migrate 
to wide regions of the protein13. A series of isomerizations could yield the reduction of a 
critical cysteine important for generation of CADASIL NOTCH3 N-terminal epitopes, even 
if the CADASIL mutation is not at the N-terminus. Of note, remote effects of NOTCH3 
mutation have been reported before; separate mutations in NOTCH3 have previously been 
observed to affect glycosylation at a single site14.
The model that CADASIL NOTCH3 N-terminal epitope unmasking is gated by a critical 
cysteine is experimentally testable; using the described antibodies, it may be feasible to 
perform mutagenesis experiments to identify the cysteine residue(s) required for generation 
of N-terminal structural changes. Another possibility is that other factors (e.g. Notch-
binding matrix proteins10, 15–18), not active in our expression system, bind specifically to 
NOTCH3 with a reduced cysteine. Subsequently, this factor could facilitate the unmasking 
of N-terminal epitopes in mutant NOTCH3 protein. The antibodies to NOTCH3 described 
herein could be utilized in biochemical assays to identify such factors.
Eventual identification of molecular pathways leading to exposure of new epitopes in 
NOTCH3 could provide insight into biochemical pathways involved in small vessel 
pathology. As such, our novel observations provide a launch point to investigating structural 
alterations of NOTCH3 as a key target in cerebral small vessel disease.
4. Materials and Methods
Generation of polyclonal antibodies
Two peptide sequences from human NOTCH3 were used to immunize rabbits (Figure 1A). 
Immunization of amino acids 64–80 (ACLCPPGWVGERCQLED) resulted in antisera 5209 
and 5210. Immunization of amino acids 85–95 with the R90C substitution 
(GPCAGCGVCQS) resulted in antisera 2078 and 2079. For some studies, 5209 and 5210 
were pooled and affinity purified against the immunizing peptide. 2078 and 2079 were 
tested separately and both exhibited the same specificity for CADASIL arteries and for 
reduced purified NOTCH3 protein. Since both 2078 and 2079 reacted against CADASIL 
tissues with diverse mutations and to wild type and R90C proteins, we reasoned that the 
antisera was not specific for the R90C mutant. These antibodies were used as crude sera in 
experiments, unless specified.
The specificity of antisera was determined in multiple experiments, described in Results. 
First, all sera were found to react avidly against CADASIL but not against control tissues. 
Second, all sera had significantly greater reactivity with reduced NOTCH3-Fc compared to 
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Fc control protein. Third, no specific reactivity with vessels or purified protein was observed 
with pre-immune sera. Fourth, reactivity of 5209 and 5210 was more than 30- and 50-fold 
higher against reduced NOTCH3 compared to NOTCH1 and NOTCH2. 2078 and 2079 
reacted two- and six-fold higher against NOTCH3 compared to NOTCH1 and NOTCH2. 
Thus, 5209 and 5210 were significantly more specific than 2078 and 2079 for NOTCH3.
Immunohistochemistry
Brain tissue and genetic mutations in NOTCH3 from six CADASIL patients have been 
described before10. The study was granted an exemption from IRB review. We examined 
two additional patients with the mutations R153C and R141C. Locations of mutations of 
these patients are shown in Figure 1A. Control patients have been described elsewhere11. 
Tissue was processed into formalin-fixed, paraffin embedded sections followed by citrate 
mediated antigen retrieval. Control stains were performed on tissue sections with anti-H2 
(sc-59467; Santa Cruz Biotechnology) to validate antigenicity of brain proteins in archival 
material. Cell lines stably expressing NOTCH3 were derive from human embryonic kidney 
293 (293) cells stably transfected with plasmids directing the expression of wildt ype or 
mutant human NOTCH3 and have been previously described 12. Cells were collected by 
centrifugation, fixed in formalin, and then processed using the same procedure used for 
brain tissue. All staining was performed using Vector Elite ABC reagents.
Epitope characterization
The production and purification of recombinant NOTCH3 has been described elsewhere 12. 
The protein contains EGF-like repeats 1–27 from human NOTCH3 fused to mouse Fc. 
Briefly, 293 cell lines stably transfected with NOTCH3-Fc constructs were shifted to serum 
free media. Media was collected and then passed over a protein A agarose column. Fusion 
protein was eluted at with acidic buffer, immediately neutralized with Tris pH 7.4, and then 
extensively dialyzed. Mouse Fc was purchased from R&D Systems (Minneapolis, MN). 
Chemicals were purchased from Sigma-Aldrich.
To investigate determinants that unmask NOTCH3 epitopes, chemicals that exert predicted 
effects on proteins were mixed with NOTCH3 protein. For alkylation experiments, proteins 
were mixed with reductants for 60 minutes at 37°C, and then a 10-fold molar excess of 
alkylating agent (compared to thiol reductants) was added for an additional 60 minutes. 
Protein (50ng) was then spotted on nitrocellulose. Protein spots were allowed to dry 
completely, and the filter was then rinsed extensively to remove small molecules. Primary 
antibodies were added at 1:100 overnight, followed by detection with infrared labeled 
secondary antibodies which were detected on a flatbed scanner (Licor Biosciences, Lincoln, 
NE).
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Highlights
• Four NOTCH3 antibodies specifically recognize degenerating arteries in 
CADASIL.
• These antibodies recognize epitopes in chemically reduced, but not denatured, 
NOTCH3 protein.
• This is the first evidence of structural changes in NOTCH3 in small vessel 
disease in human brain.
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Figure 1. 
Antibodies to human NOTCH3 and reactivity with CADASIL white matter arteries. (A) A 
schematic of the NOTCH3 protein and expanded view of the N-terminus. Sequences 
localized to the end of the first EGF-like repeat and the beginning of the second EGF-like 
repeat, highlighted with horizontal bars, were used as immunogens to generated N-terminal 
NOTCH3 antibodies 5209, 5210, 2078, and 2079. Gain or loss of cysteine mutations are 
depicted by shaded circles with or without a “C,” respectively, at the bottom right side of 
(A). Small penetrating white matter vessels from CADASIL brains were examined by 
immunohistochemistry using 5210 (B) and 2079 (C). Insets in (B) and (C) show negative 
vascular staining patterns using preimmune serum. Positive vascular staining was seen with 
5209 and 2078, and corresponding preimmune serum failed to react with CADASIL vessels.
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Figure 2. 
NOTCH3 N-terminal epitopes in leptomeningeal arteries in CADASIL and controls. 
Antibodies 5210 (A, B) and 2079 (C, D) stained leptomeningeal arteries of a CADASIL 
brain (A, C) but not those of a control brain (B, D). Staining in CADASIL was observed in 
the medial layer of arteries that showed intense thickening due to intimal hyperplasia and 
medial fibrosis in CADASIL. Antibodies 5209 and 2078 resulted in similar staining 
patterns.
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Figure 3. 
Immunohistochemistry of Notch3 N-terminal epitopes in 293 cell lines. overexpressing wild 
type or mutant NOTCH3. Human 293 cell lines were collected, fixed, and paraffin 
embedded prior to analysis by immunohistochemistry. (A) Key showing antibodies used to 
analyze cell lines. N3 MO1, a monoclonal against the N-terminus of NOTCH3, was used as 
a positive control to verify NOTCH3 expression. Antibodies were each applied to vector 
negative control 293 (B), wild type NOTCH3 (C), and R90C NOTCH3 (D) transfected cell 
lines. N-terminal antibodies 5210 and 2079 did not stain cells overexpressing NOTCH3.
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Figure 4. 
Unmasking of NOTCH3 N-terminal epitopes in recombinant NOTCH3 protein. 
Recombinant fusions of NOTCH3 ectodomain to mouse Fc were purified to homogeneity 
from 293 cell lines. Fifty ng of wild type NOTCH3 (WT), R90C NOTCH3 (R90C), or 
mouse Fc (C) were treated with chemicals indicated for 60 minutes at 37°C (or at 65°C 
without chemicals) and then spotted on nitrocellulose. 5210 or 2079 were used to detect N-
terminal NOTCH3 epitopes. Untreated protein (UN) was applied on the left-most column. 
Conditions included 10 mM dithiothreitol (DTT), heat, 1% SDS, 6M urea, 6M guanidinium 
HCl (Guan), 0.3% acrylamide (Acry), and 0.5M hydrochloric acid (HCl). To verify presence 
of proteins, blots were also probed against Fc (bottom panel).
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Figure 5. 
Effect of reducing reagents on N-terminal epitopes in NOTCH3. As in Figure 4, purified 
recombinant NOTCH3 ectodomain fused to mouse Fc were treated prior to application to 
nitrocellulose filters. Proteins were treated with increasing concentrations of indicated 
reducing agents for 60 minutes at 37°C. Antibody binding to wild type NOTCH3-Fc (WT) 
and R90C NOTCH3-Fc (R90C) protein is shown. Similar results were obtained with the 
5210 (A) and 2079 (B) antibodies. Chemical used to treat protein include thiol reductants 
dithiothreitol (DTT) and beta-mercaptoethanol (βME) and the phosphorus-based reductant 
tris(2-carboxyethyl)phosphine (TCEP). (C–D) After reduction with 10mM DTT, NOTCH3 
protein was alkylated with either iodoacetic acid (IAA; 100mM) or acrylamide (acry; 0.3%) 
and applied to nitrocellulose filters. Filters were then probed with 5210 (C) or 2079 (D). 
Alkylation had no effect on epitope recognition by either N-terminal NOTCH3 polyclonal 
antiserum.
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